138 related articles for article (PubMed ID: 17211470)
1. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.
Kamoshida S; Suzuki M; Shimomura R; Sakurai Y; Komori Y; Uyama I; Tsutsumi Y
Br J Cancer; 2007 Jan; 96(2):277-83. PubMed ID: 17211470
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
4. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K
Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912
[TBL] [Abstract][Full Text] [Related]
5. Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.
Popat S; Wort R; Houlston RS
BMC Cancer; 2006 Jun; 6():150. PubMed ID: 16753067
[TBL] [Abstract][Full Text] [Related]
6. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
Lenz HJ; Danenberg KD; Leichman CG; Florentine B; Johnston PG; Groshen S; Zhou L; Xiong YP; Danenberg PV; Leichman LP
Clin Cancer Res; 1998 May; 4(5):1227-34. PubMed ID: 9607581
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
[TBL] [Abstract][Full Text] [Related]
8. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
Boku N; Ohtsu A; Yoshida S; Shirao K; Shimada Y; Hyodo I; Saito H; Miyata Y;
Jpn J Clin Oncol; 2007 Apr; 37(4):275-81. PubMed ID: 17522103
[TBL] [Abstract][Full Text] [Related]
9. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
[TBL] [Abstract][Full Text] [Related]
10. [Effect of low-dose CDDP/5-FU therapy on thymidylate synthase content].
Kosaka T; Ueshige N; Sugaya J; Nakano Y; Takashima S
Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():450-3. PubMed ID: 9589051
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneous expression of thymidylate synthase in gastric cancer.
Chung-Kang C; Ohno M; Nishimura K; Kuroda Y
Hepatogastroenterology; 2006; 53(69):458-62. PubMed ID: 16795992
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy.
Yeh KH; Shun CT; Chen CL; Lin JT; Lee WJ; Lee PH; Chen YC; Cheng AL
Hepatogastroenterology; 1999; 46(25):610-5. PubMed ID: 10228869
[TBL] [Abstract][Full Text] [Related]
14. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
[TBL] [Abstract][Full Text] [Related]
15. Level of 5-fluorodeoxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study.
Yamamoto S; Kubota K
J Exp Clin Cancer Res; 2005 Sep; 24(3):457-62. PubMed ID: 16270533
[TBL] [Abstract][Full Text] [Related]
16. Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs.
Kamoshida S; Suzuki M; Sakurai Y; Ochiai M; Kimura F; Kuwao S; Sakamoto K; Sugimoto Y; Fukushima M; Tsutsumi Y
Oncol Rep; 2006 Oct; 16(4):721-7. PubMed ID: 16969485
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Fukui Y; Oka T; Nagayama S; Danenberg PV; Danenberg KD; Fukushima M
Int J Mol Med; 2008 Dec; 22(6):709-16. PubMed ID: 19020767
[TBL] [Abstract][Full Text] [Related]
18. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy.
Monden N; Abe S; Hishikawa Y; Yoshimura H; Kinugasa S; Dhar DK; Tachibana M; Nagasue N
Int J Surg Investig; 1999; 1(1):3-10. PubMed ID: 11817335
[TBL] [Abstract][Full Text] [Related]
19. [Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer].
Nakata B; Chung YS; Ogawa M; Maeda K; Inoue T; Yamashita Y; Sowa M
Gan To Kagaku Ryoho; 1996 Jun; 23 Suppl 2():151-3. PubMed ID: 8678559
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
